Use of nintedanib for the treatment of idiopathic pulmonary fibrosis: multi-centre real life experience in Germany
F Bonella, M Kreuter, L Hagmeyer, C Neurohr, K Milger, C Keller, M Kohlhäufl, J Müller-Quernheim, A Prasse · Pneumologie · 2016 · Heft 02
Bibliografische Angaben
Zusammenfassung
Background: Idiopathic pulmonary fibrosis (IPF) is a chronic progressive interstitial lung disease with a poor life expectancy. Nintedanib is a multiple tyrosine kinases inhibitor recently approved for the treatment of IPF, slowing disease progression by reducing the annual decline in lung function. Here we report the results of a large cohort of IPF patients who received nintedanib within a compassionate-use program (CUP) in Germany. Methods: Since May 2014 62 IPF patients were treated with nintedanib inside the CUP in 9 centers across Germany. Patients should have a diagnosis of IPF based upon the ATS/ERS/JRS/…
